- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | TriSalus Life Sciences secures ~$50M of debt financing with OrbiMed | 1 | Seeking Alpha | ||
| Di | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.04. | TriSalus Life Sciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.04. | TriSalus Life Sciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 02.04. | TriSalus Life Sciences, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 01.04. | TriSalus Life Sciences GAAP EPS of -$1.56 | 1 | Seeking Alpha | ||
| 01.04. | TriSalus Life Sciences, Inc. Q4 sales increase | - | RTTNews | ||
| 01.04. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update | 82 | Business Wire | DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided... ► Artikel lesen | |
| 12.03. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.03. | TriSalus drug nelitolimod gets WHO, USAN nod | 1 | Investing.com | ||
| 25.01. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.01. | Quest Diagnostics Enters Into Research Collaboration With TriSalus | 411 | AFX News | WASHINGTON (dpa-AFX) - Quest Diagnostics Inc. (DGX) has announced that its subsidiary, Haystack Oncology, the developer of Haystack MRD, has entered into a research collaboration with TriSalus... ► Artikel lesen | |
| 05.01. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.23 | TriSalus Life Sciences files to sell 5.9 million shares for holders | 1 | Seeking Alpha | ||
| 15.12.23 | TriSalus Life Sciences, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 15.12.23 | TriSalus Life Sciences, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.11.23 | TriSalus Life Sciences GAAP EPS of -$0.13, revenue of $5.2M | 1 | Seeking Alpha | ||
| 14.11.23 | TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update | 199 | Business Wire | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), a publicly traded oncology company integrating its novel delivery technology with immunotherapy to transform treatment for... ► Artikel lesen | |
| 10.08.23 | TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation | 227 | Business Wire | DENVER & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 9,550 | +2,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 3,690 | -0,54 % | What's Going On With Rocket Lab Shares Today? | ||
| BOIRON | 34,000 | +0,15 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| MEDICINOVA | 1,340 | +24,07 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,880 | -1,01 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,520 | +7,32 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| HARROW | 10,385 | -2,40 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| SHINECO | 0,770 | -5,88 % | SHINECO, INC. - 8-K, Current Report | ||
| CUMBERLAND PHARMACEUTICALS | 1,630 | +3,82 % | CUMBERLAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 3,200 | +0,63 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| BAYER | 28,020 | -0,39 % | Bayer - hier fliegt heute der Deckel weg | Bayer springt heute regelrecht nach oben. Denn die Aktie verzeichnet aktuell ein Plus von rund fünf Prozent. Damit kostet der Titel nun 28,59 EUR. Ist dieser Anstieg das Signal für Gewinnmitnahmen?... ► Artikel lesen | |
| MERCK KGAA | 152,00 | +1,13 % | Dividendenbekanntmachungen (29.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,139 HKD 0,0166 EUR ACROW LIMITED AU0000006124 0,0285 AUD 0,0174 EUR AGNC INVESTMENT... ► Artikel lesen | |
| NOVO NORDISK | 114,02 | -2,21 % | Novo Nordisk: Zahlen sind ein dickes Ding | Das Abnehm-Medikament Wegovy geht weg wie die sprichwörtlichen warmen Semmeln: Der Umsatz damit hat sich im ersten Quartal mehr als verdoppelt, der Hersteller Novo Nordisk übertraf die Gewinnschätzungen.... ► Artikel lesen | |
| CANOPY GROWTH | 9,500 | +0,21 % | Breaking News: Marihuana-Hammer - Tilray, Curaleaf, Canopy & Co explodieren | Das kommt überraschend: In Amerika ändert sich die Einschätzung von Marihuana. Die Drogenbehörde DEA ändert ihre Einstufung von Marihuana auf Schedule III. Damit erkennt sie die medizinische Verwendung... ► Artikel lesen |
TRISALUS LIFE SCIENCES INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 9,560 Euro und damit +2,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
